SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-21-008725
Filing Date
2021-06-30
Accepted
2021-06-30 17:23:43
Documents
12
Period of Report
2021-06-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20210630x8k.htm   iXBRL 8-K 41453
  Complete submission text file 0001558370-21-008725.txt   164992

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20210630.xsd EX-101.SCH 3193
3 EX-101.LAB plx-20210630_lab.xml EX-101.LAB 16160
4 EX-101.PRE plx-20210630_pre.xml EX-101.PRE 10905
5 EXTRACTED XBRL INSTANCE DOCUMENT plx-20210630x8k_htm.xml XML 4870
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 211062867
SIC: 2836 Biological Products, (No Diagnostic Substances)